214 related articles for article (PubMed ID: 14581348)
1. SU5416 plus interferon alpha in advanced renal cell carcinoma: a phase II California Cancer Consortium Study with biological and imaging correlates of angiogenesis inhibition.
Lara PN; Quinn DI; Margolin K; Meyers FJ; Longmate J; Frankel P; Mack PC; Turrell C; Valk P; Rao J; Buckley P; Wun T; Gosselin R; Galvin I; Gumerlock PH; Lenz HJ; Doroshow JH; Gandara DR;
Clin Cancer Res; 2003 Oct; 9(13):4772-81. PubMed ID: 14581348
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma.
Kuenen BC; Tabernero J; Baselga J; Cavalli F; Pfanner E; Conte PF; Seeber S; Madhusudan S; Deplanque G; Huisman H; Scigalla P; Hoekman K; Harris AL
Clin Cancer Res; 2003 May; 9(5):1648-55. PubMed ID: 12738717
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of the Flk-1 tyrosine kinase inhibitor SU5416 in advanced melanoma.
Peterson AC; Swiger S; Stadler WM; Medved M; Karczmar G; Gajewski TF
Clin Cancer Res; 2004 Jun; 10(12 Pt 1):4048-54. PubMed ID: 15217937
[TBL] [Abstract][Full Text] [Related]
4. A multinational phase II trial of bevacizumab with low-dose interferon-α2a as first-line treatment of metastatic renal cell carcinoma: BEVLiN.
Melichar B; Bracarda S; Matveev V; Alekseev B; Ivanov S; Zyryanov A; Janciauskiene R; Fernebro E; Mulders P; Osborne S; Jethwa S; Mickisch G; Gore M; van Moorselaar RJ; Staehler M; Magne N; Bellmunt J;
Ann Oncol; 2013 Sep; 24(9):2396-402. PubMed ID: 23803225
[TBL] [Abstract][Full Text] [Related]
5. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial.
Escudier B; Pluzanska A; Koralewski P; Ravaud A; Bracarda S; Szczylik C; Chevreau C; Filipek M; Melichar B; Bajetta E; Gorbunova V; Bay JO; Bodrogi I; Jagiello-Gruszfeld A; Moore N;
Lancet; 2007 Dec; 370(9605):2103-11. PubMed ID: 18156031
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of the antiangiogenic agent SU5416 in patients with advanced soft tissue sarcomas.
Heymach JV; Desai J; Manola J; Davis DW; McConkey DJ; Harmon D; Ryan DP; Goss G; Quigley T; Van den Abbeele AD; Silverman SG; Connors S; Folkman J; Fletcher CD; Demetri GD
Clin Cancer Res; 2004 Sep; 10(17):5732-40. PubMed ID: 15355900
[TBL] [Abstract][Full Text] [Related]
7. Phase I trial of sorafenib in combination with IFN alpha-2a in patients with unresectable and/or metastatic renal cell carcinoma or malignant melanoma.
Escudier B; Lassau N; Angevin E; Soria JC; Chami L; Lamuraglia M; Zafarana E; Landreau V; Schwartz B; Brendel E; Armand JP; Robert C
Clin Cancer Res; 2007 Mar; 13(6):1801-9. PubMed ID: 17363536
[TBL] [Abstract][Full Text] [Related]
8. A phase II study of razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis.
Braybrooke JP; O'Byrne KJ; Propper DJ; Blann A; Saunders M; Dobbs N; Han C; Woodhull J; Mitchell K; Crew J; Smith K; Stephens R; Ganesan TS; Talbot DC; Harris AL
Clin Cancer Res; 2000 Dec; 6(12):4697-704. PubMed ID: 11156222
[TBL] [Abstract][Full Text] [Related]
9. Improved tolerability and quality of life with maintained efficacy using twice-daily low-dose interferon-alpha-2b: results of a randomized phase II trial of low-dose versus intermediate-dose interferon-alpha-2b in patients with metastatic renal cell carcinoma.
Tannir NM; Cohen L; Wang X; Thall P; Mathew PF; Jonasch E; Siefker-Radtke A; Pagliaro LC; Ng CS; Logothetis C
Cancer; 2006 Nov; 107(9):2254-61. PubMed ID: 17029276
[TBL] [Abstract][Full Text] [Related]
10. A randomized Phase II trial of the antiangiogenic agent SU5416 in hormone-refractory prostate cancer.
Stadler WM; Cao D; Vogelzang NJ; Ryan CW; Hoving K; Wright R; Karrison T; Vokes EE
Clin Cancer Res; 2004 May; 10(10):3365-70. PubMed ID: 15161690
[TBL] [Abstract][Full Text] [Related]
11. Phase II trial of interleukin 2, interferon alpha, and 5-fluorouracil in metastatic renal cell cancer: a cytokine working group study.
Dutcher JP; Logan T; Gordon M; Sosman J; Weiss G; Margolin K; Plasse T; Mier J; Lotze M; Clark J; Atkins M
Clin Cancer Res; 2000 Sep; 6(9):3442-50. PubMed ID: 10999727
[TBL] [Abstract][Full Text] [Related]
12. Results of a Phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies.
Stopeck A; Sheldon M; Vahedian M; Cropp G; Gosalia R; Hannah A
Clin Cancer Res; 2002 Sep; 8(9):2798-805. PubMed ID: 12231519
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of sorafenib plus interferon alfa-2b as first- or second-line therapy in patients with metastatic renal cell cancer.
Gollob JA; Rathmell WK; Richmond TM; Marino CB; Miller EK; Grigson G; Watkins C; Gu L; Peterson BL; Wright JJ
J Clin Oncol; 2007 Aug; 25(22):3288-95. PubMed ID: 17664476
[TBL] [Abstract][Full Text] [Related]
14. Phase I/II trial of temsirolimus combined with interferon alfa for advanced renal cell carcinoma.
Motzer RJ; Hudes GR; Curti BD; McDermott DF; Escudier BJ; Negrier S; Duclos B; Moore L; O'Toole T; Boni JP; Dutcher JP
J Clin Oncol; 2007 Sep; 25(25):3958-64. PubMed ID: 17761980
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of SU5416, a small molecule vascular endothelial growth factor tyrosine kinase receptor inhibitor, in patients with refractory multiple myeloma.
Zangari M; Anaissie E; Stopeck A; Morimoto A; Tan N; Lancet J; Cooper M; Hannah A; Garcia-Manero G; Faderl S; Kantarjian H; Cherrington J; Albitar M; Giles FJ
Clin Cancer Res; 2004 Jan; 10(1 Pt 1):88-95. PubMed ID: 14734456
[TBL] [Abstract][Full Text] [Related]
16. Complete radiological and metabolic response of metastatic renal cell carcinoma to SU5416 (semaxanib) in a patient with probable von Hippel-Lindau syndrome.
Jennens RR; Rosenthal MA; Lindeman GJ; Michael M
Urol Oncol; 2004; 22(3):193-6. PubMed ID: 15271314
[TBL] [Abstract][Full Text] [Related]
17. Phase I trial of PEG-interferon and recombinant IL-2 in patients with metastatic renal cell carcinoma.
George S; Hutson TE; Mekhail T; Wood L; Finke J; Elson P; Dreicer R; Bukowski RM
Cancer Chemother Pharmacol; 2008 Jul; 62(2):347-54. PubMed ID: 17909807
[TBL] [Abstract][Full Text] [Related]
18. Interferon alfa-2b three times daily and thalidomide in the treatment of metastatic renal cell carcinoma.
Hernberg M; Virkkunen P; Bono P; Ahtinen H; Mäenpää H; joensuu H
J Clin Oncol; 2003 Oct; 21(20):3770-6. PubMed ID: 14551295
[TBL] [Abstract][Full Text] [Related]
19. 89Zr-bevacizumab PET visualizes heterogeneous tracer accumulation in tumor lesions of renal cell carcinoma patients and differential effects of antiangiogenic treatment.
Oosting SF; Brouwers AH; van Es SC; Nagengast WB; Oude Munnink TH; Lub-de Hooge MN; Hollema H; de Jong JR; de Jong IJ; de Haas S; Scherer SJ; Sluiter WJ; Dierckx RA; Bongaerts AH; Gietema JA; de Vries EG
J Nucl Med; 2015 Jan; 56(1):63-9. PubMed ID: 25476536
[TBL] [Abstract][Full Text] [Related]
20. Maximal COX-2 immunostaining and clinical response to celecoxib and interferon alpha therapy in metastatic renal cell carcinoma.
Rini BI; Weinberg V; Dunlap S; Elchinoff A; Yu N; Bok R; Simko J; Small EJ
Cancer; 2006 Feb; 106(3):566-75. PubMed ID: 16369983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
